Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials

Conclusions There is currently no evidence that phosphate-binder treatment reduces mortality compared to placebo in adults with CKD. It is not clear whether the higher mortality with calcium versus sevelamer reflects whether there is net harm associated with calcium, net benefit with sevelamer, both, or neither. Iron-based binders show evidence of greater phosphate lowering that warrants further examination in randomized trials.
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research